English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Objective  To investigate the effect of healthcare provider ( HCP ) type (primary vs. specialist) on glycaemic control and other treatment parameters.    Research design and methods  Study of Once‐Daily Levemir ( SOLVE  ™ ) is an international, 24‐week, observational study of insulin initiation in people with type 2 diabetes.    Results  A total of 17,374 subjects were included, comprising 4144 (23.9%) primary care subjects. Glycaemic control improved in both  HCP  groups from baseline to final visit [glycated haemoglobin (HbA1c) −1.2 ± 1.4% (−13.1 ± 15.3 mmol/mol) and −1.3 ± 1.6% (−14.2 ± 17.5 mmol/mol), respectively]. After adjustment for known confounders, there was no statistically significant effect of  HCP  group on final HbA1c [−0.04%, 95% confidence interval ( CI ) −0.09 to −0.01 (−0.4 mmol/mol, 95%  CI  −1.0−0.1 mmol/mol), p = 0.1590]. However, insulin doses at the final visit were higher in primary care patients (+0.06, 95%  CI  0.06–0.07 U/kg, p &lt; 0.0001). Logistic regression demonstrated a significant effect of  HCP  type (primary vs. specialist care) on hypoglycaemia risk [odds ratio ( OR ) 0.75, 95%  CI  0.64–0.87, p = 0.0002]. Primary care physicians took more time to train patients and had more frequent contact with patients than specialists (both p &lt; 0.0001).    Conclusions  Primary care physicians and specialists achieved comparable improvements in glycaemic control following insulin initiation.

Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations